br Huang CP Tsai MF Chang TH et al ALDH
3. Huang CP, Tsai MF, Chang TH, et al. ALDH-positive lung cancer stem 145022-92-0 confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 2013; 328:144-51.
4. Shien K, Toyooka S, Yamamoto H, et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 2013; 73:3051-61.
5. Leon G, MacDonagh L, Finn SP, Cuffe S, Barr MP. Cancer stem cells in drug resistant lung cancer: targeting cell surface markers and signaling pathways. Pharmacol Ther 2016; 158:71-90.
6. Arasada RR, Amann JM, Rahman MA, Huppert SS, Carbone DP. EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res 2014; 74:5572-84.
7. Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelialemesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009; 119:3626-36.
10. Codony-Servat C, Codony-Servat J, Karachaliou N, et al. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant nonesmall-cell lung cancer (NSCLC). Oncotarget 2017; 8:47305-16.
11. Karachaliou N, Chaib I, Cardona AF, et al. Common co-activation of AXL and CDCP1 in EGFR-mutationepositive nonesmall cell lung cancer associated with poor prognosis. EBioMedicine 2018; 29:112-27.
13. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M muta-tion and BRCA1 mRNA expression in erlotinib-treated advanced nonesmall-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011; 17: 1160-8.
14. Shao C, Sullivan JP, Girard L, et al. Essential role of aldehyde dehydrogenase 1A3 for the maintenance of nonesmall cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res 2014; 20:4154-66.
15. Dang TP, Eichenberger S, Gonzalez A, Olson S, Carbone DP. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of trans-genic mice. Oncogene 2003; 22:1988-97. 16. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133þ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106:16281-6.
19. Thakur R, Trivedi R, Rastogi N, Singh M, Mishra DP. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep 2015; 5:10194.
20. Abhold EL, Kiang A, Rahimy E, et al. EGFR kinase promotes acquisition of stem cellelike properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One 2012; 7:e32459.
21. Sette G, Salvati V, Mottolese M, et al. Tyr1068-phosphorylated epidermal growth factor receptor EGFR predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Cell Death Dis 2015; 6: e1850. Jordi Codony-Servat et al
22. Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, et al. Stem cellelike ALDH(-bright) cellular states in EGFR-mutant nonesmall cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural poly-phenol silibinin. Cell Cycle 2013; 12:3390-404.
27. Hashida S, Yamamoto H, Shien K, et al. Acquisition of cancer stem cellelike properties in nonesmall cell lung cancer with acquired resistance to afatinib. Cancer Sci 2015; 106:1377-84.
28. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15:504-14. 29. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010; 70:9937-48.
31. Ojo D, Lin X, Wu Y, Cockburn J, Bane A, Tang D. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. Cancer Lett 2018; 426:4-13.
Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From
Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
7 Q25 Hitoshi Tsugawa,1 Chihiro Kato,2 Hideki Mori,3 Juntaro Matsuzaki,4 Kaori Kameyama,5
9 Hideyuki Saya,6 Masanori Hatakeyama,7 Makoto Suematsu,1 and Hidekazu Suzuki8 10 11 1Department of Biochemistry, 2Medical Education Center, 5Department of Pathology, 6Division of Gene Regulation, Institute for 12 Advanced Medical Research, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan; 3Division of Gastroenterology 13 and Hepatology, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan; 4Division of Molecular and 14 Cellular Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan; 7Division of Microbiology, Graduate 15 School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan; 8Department of Gastroenterology and Hepatology, Tokai 16 University School of Medicine, Isehara City, Kanagawa, Japan